Reistone Biopharma
Focusing on rapidly developing innovative medicines through global collaborations within Research and Development.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | $100m | Series A | |
| Total Funding | 000k | ||
Related Content
Reistone Biopharma is a clinical-stage biopharmaceutical company that develops medicines for autoimmune and inflammatory diseases. The company has a particular focus on inflammatory bowel disease.
Founded in January 2018, Reistone Biopharma operates in Shanghai and Beijing, China, and Boston, USA. The company is actively engaged in clinical trials, including a successful Phase 2 trial for its JAK inhibitor for patients with moderate-to-severe ulcerative colitis. In May 2022, the company announced the completion of a Series A financing round of nearly USD 100 million, led by Huagai Capital.
Reistone Biopharma's business model is centered on the research and development of novel drugs to address unmet medical needs in the autoimmune and inflammatory disease market. The company's primary clients are patients suffering from these conditions, and it operates within the global biopharmaceutical industry.
Keywords: biopharmaceutical, clinical-stage, autoimmune diseases, inflammatory diseases, inflammatory bowel disease, JAK inhibitor, ulcerative colitis, drug development, clinical trials, Series A